Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
PeptiDream Inc. functions as a biopharmaceutical enterprise, concentrating on the identification and progression of therapeutic compounds such as constrained peptides, small molecules, and peptide-drug conjugates. The company's unique product pipeline is underpinned by its proprietary Peptide Discovery Platform System (PDPS), an advanced technology specifically designed for the development of peptide-based drugs. Additionally, PeptiDream maintains an exclusive licensing and collaborative research partnership with Takeda Pharmaceutical Company Limited, aimed at creating peptide drug conjugates for the treatment of neuromuscular conditions. Established in 2006, the company's primary offices are situated in Kawasaki, Japan.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, ov
Target Price
The average target price of 4587.T is 2626 and suggests 143% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc